Alembic Pharmaceuticals submits press release
Alembic Pharmaceuticals has submitted press release stating that Alembic Pharmaceuticals receives USFDA Final approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg.
The above information is a part of company’s filings submitted to BSE.
